Unicycive Therapeutics Inc.
13F holders, Q3 2024 (September 30)29holders +5
12new positions
7sold out
$0.41avg. 13F price*
At the end of Q3 2024, 29 institutions reported holding Unicycive Therapeutics Inc. in their 13F filings, up 5 from Q2 2024. 12 opened new positions and 7 sold out. The largest holders were Great Point Partners LLC ($3.5M), Octagon Capital Advisors LP ($3.5M) and Logos Global Management LP ($2.1M).
- Company
- Unicycive Therapeutics Inc.
- CUSIP
- 90466Y103
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 12 | $13.1M |
| Exits | 7 | $3.7M |
All 13F filers, Q2 2024 → Q3 2024: 35,219,890 shares bought and 7,450,569 shares sold, net +27,769,321 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 29 holders
| Great Point Partners LLC | 1.05% | New | 8,559,000 | $3.5M |
| Octagon Capital Advisors LP | 0.56% | New | 8,559,000 | $3.5M |
| Logos Global Management LP | 0.23% | Add +46.4% | 5,078,927 | $2.1M |
| Walleye Capital LLC | 0.02% | New | 5,000,000 | $2.0M |
| Vivo Capital, LLC | 0.15% | Add +28.8% | 4,470,152 | $1.8M |
| Silverarc Capital Management, LLC | 0.37% | New | 4,000,000 | $1.6M |
| Nantahala Capital Management, LLC | 0.10% | No change | 2,820,358 | $1.2M |
| Alyeska Investment Group, L.P. | 0.00% | New | 2,250,000 | $918K |
| Acuta Capital Partners, LLC | 0.65% | New | 1,979,199 | $807K |
| Altium Capital Management LLC | 0.18% | New | 1,473,000 | $601K |
| Vanguard Group Inc. | 0.00% | No change | 1,138,220 | $464K |
| LPL Financial LLC | 0.00% | Add +448.2% | 466,005 | $190K |
| Geode Capital Management, LLC | 0.00% | Add +40.8% | 402,398 | $164K |
| Goldman Sachs Group Inc. | 0.00% | Add +0.1% | 93,424 | $38K |
| Bleakley Financial Group, LLC | 0.00% | New | 80,000 | $33K |
| Virtu Financial LLC | 0.00% | Add +566.8% | 73,975 | $30K |
| BlackRock, Inc. | 0.00% | — | 71,821 | $29K |
| XTX Topco Ltd | 0.00% | New | 70,784 | $29K |
| State Street Corp. | 0.00% | No change | 43,936 | $18K |
| Jane Street Group, LLC | 0.00% | New | 41,249 | $17K |
| Northern Trust Corp. | 0.00% | No change | 23,998 | $10K |
| Two Sigma Securities, LLC | 0.00% | New | 23,266 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +23.3% | 22,782 | $9K |
| Captrust Financial Advisors | 0.00% | No change | 18,800 | $8K |
| Tandem Capital Management Corp. | 0.00% | No change | 15,500 | $6K |
| Creative Planning | 0.00% | New | 10,231 | $4K |
| Bank of America Corp. | 0.00% | Add +48.9% | 332 | $135 |
| JPMorgan Chase & Co. | 0.00% | Add +195.7% | 207 | $84 |
| UBS Group AG | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is UNICYCIVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Unicycive Therapeutics Inc. the manager owns.